150 related articles for article (PubMed ID: 30738455)
21. [Predictive Value of Newly Diagnosed IgG Level in Patients with IgG-type Multiple Myeloma after Initial Treatment].
Li Q; Hu CD; Zhang CC; Jiang W; Wang QR; Sun YC; Yang JL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Dec; 29(6):1825-1830. PubMed ID: 34893118
[TBL] [Abstract][Full Text] [Related]
22. [Prognostic value of serum IL-6 in patients with multiple myeloma].
Xing LJ; Xu Y; An G; Deng SH; Sui WW; Li F; Zhou DH; Zhao YZ; Qiu LG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Dec; 21(6):1492-5. PubMed ID: 24370035
[TBL] [Abstract][Full Text] [Related]
23. Incidence of contrast-induced nephropathy in patients with multiple myeloma undergoing contrast-enhanced CT.
Pahade JK; LeBedis CA; Raptopoulos VD; Avigan DE; Yam CS; Kruskal JB; Pedrosa I
AJR Am J Roentgenol; 2011 May; 196(5):1094-101. PubMed ID: 21512075
[TBL] [Abstract][Full Text] [Related]
24. [Prognostic Value of Corrected Levels of Serum Calcium and Serum Lactate Dehydrogenase for Newly Diagnosed Multiple Myeloma Patients].
Xie YM; Cui YJ; Li H; Pan XR; Xu YX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Jun; 27(3):844-849. PubMed ID: 31204942
[TBL] [Abstract][Full Text] [Related]
25. The Association Between Low T3 Syndrome and Survival in Patients With Newly Diagnosed Multiple Myeloma: A Retrospective Study.
Pan Q; Jian Y; Zhang Y; Zhang W; Chen Z; Yang Y; Liu A; Wang G
Technol Cancer Res Treat; 2022; 21():15330338221094422. PubMed ID: 35443837
[No Abstract] [Full Text] [Related]
26. Laboratory Features of Newly Diagnosed Multiple Myeloma Patients.
Hussain A; Almenfi HF; Almehdewi AM; Hamza MS; Bhat MS; Vijayashankar NP
Cureus; 2019 May; 11(5):e4716. PubMed ID: 31355076
[TBL] [Abstract][Full Text] [Related]
27. [Clinical Research about Risk Factors and Reversible Predictors in Renal Impairment due to Multiple Myeloma].
Liu MM; Xu HZ; Feng XM; Zhang Y; Liu YX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Jun; 23(3):722-7. PubMed ID: 26117025
[TBL] [Abstract][Full Text] [Related]
28. Tumor load in patients with multiple myeloma: β2-microglobulin levels versus whole-body MRI.
D'Anastasi M; Notohamiprodjo M; Schmidt GP; Dürr HR; Reiser MF; Baur-Melnyk A
AJR Am J Roentgenol; 2014 Oct; 203(4):854-62. PubMed ID: 25247952
[TBL] [Abstract][Full Text] [Related]
29. [Expression of serum GDF15 and its clinical significance in multiple myeloma patients].
Zhao N; Yang J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2014 Mar; 39(3):270-5. PubMed ID: 24748192
[TBL] [Abstract][Full Text] [Related]
30. Renal impairment in patients with multiple myeloma.
Chow CC; Mo KL; Chan CK; Lo HK; Wong KS; Chan JC
Hong Kong Med J; 2003 Apr; 9(2):78-82. PubMed ID: 12668816
[TBL] [Abstract][Full Text] [Related]
31. [Prognostic analysis and assessment on the clinical staging systems of multiple myeloma--a report of 206 cases].
Tao ZF; Fu WJ; Chen YB; Yuan ZG; Wang DX; Hou J
Ai Zheng; 2006 Apr; 25(4):461-4. PubMed ID: 16613681
[TBL] [Abstract][Full Text] [Related]
32. [Clinical features and outcome analyses of newly-diagnosed multiple myeloma with extramedullary involvements].
Zhang YZ; Zhi YQ; Wang YF; Yu Y; Zhao ZG; Wang XF; Zhai QL; Sun BC
Zhonghua Yi Xue Za Zhi; 2012 Sep; 92(34):2415-8. PubMed ID: 23158665
[TBL] [Abstract][Full Text] [Related]
33. [Risk factors for coronary artery calcification in patients with end-stage renal disease].
Cui L; Xu J; Bai Y; Zhang J
Zhonghua Yi Xue Za Zhi; 2015 Oct; 95(38):3133-7. PubMed ID: 26814105
[TBL] [Abstract][Full Text] [Related]
34. [Correlation between Serum Interleukin-33, β
Wang SY; Qiu DB; Fan CH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):788-793. PubMed ID: 37356941
[TBL] [Abstract][Full Text] [Related]
35. Prognostic Significance of Blood Transfusion in Newly Diagnosed Multiple Myeloma Patients without Autologous Hematopoietic Stem Cell Transplantation.
Fan L; Fu D; Zhang J; Huang H; Wang Q; Ye Y; Xie Q
Biomed Res Int; 2017; 2017():5462087. PubMed ID: 28567420
[TBL] [Abstract][Full Text] [Related]
36. [Screening of prognostic factors and comparing of staging systems of multiple myeloma].
Li J; Wu XB; Zhou Y; Wang X; Chen JX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):926-9. PubMed ID: 22931656
[TBL] [Abstract][Full Text] [Related]
37. [Recommendations for early identification of damage to the skeleton by malignant processes, and for early diagnosis of multiple myeloma].
Adam Z; Bednarík J; Neubauer J; Chaloupka R; Fojtík Z; Vanícek J; Pour L; Cermákova Z; Scudla V; Maisnar V; Straub J; Schützová M; Gregora E; Weinreb M; Stuchlíková K; Stanícek J; Hájek R; Krejcí M; Vorlícek J;
Vnitr Lek; 2006 Nov; 52 Suppl 2():9, 11-31. PubMed ID: 18175427
[TBL] [Abstract][Full Text] [Related]
38. [Preliminary report of fludarabine, mitoxantrone and dexamethasone in treating refractory or relapsed multiple myeloma].
Luo SK; Li J; Hong WD; Zhao Y; Tong XZ
Ai Zheng; 2005 Dec; 24(12):1518-21. PubMed ID: 16351805
[TBL] [Abstract][Full Text] [Related]
39. [Prognositic factors in multiple myeloma].
Nagura E
Nihon Rinsho; 2007 Dec; 65(12):2351-6. PubMed ID: 18069282
[TBL] [Abstract][Full Text] [Related]
40. [Biochemical and immunological findings of multiple myeloma].
Asaoku H
Nihon Rinsho; 2007 Dec; 65(12):2256-60. PubMed ID: 18069270
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
